CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Revlimid for Newly Diagnosed MM – Details

Project Number PC0061-000
Brand Name Revlimid
Generic Name Lenalidomide
Strength 5, 10, 15, 25 mg capsules
Tumour Type Myeloma
Indication Multiple Myeloma (newly diagnosed)
Funding Request In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Celgene Inc.
Sponsor Celgene Inc.
Submission Date May 4, 2015
Submission Deemed Complete May 11, 2015
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ May 19, 2015
Check-point meeting July 7, 2015
pERC Meeting September 17, 2015
Initial Recommendation Issued October 1, 2015
Feedback Deadline ‡ October 16, 2015
pERC Reconsideration Meeting November 19, 2015
Final Recommendation Issued December 3, 2015
Notification to Implement Issued December 18, 2015
Therapeutic Area Multiple Myeloma, newly diagnosed
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.